Farmas USA

ARRY gracias Framus, no lo había visto. SGYP

entonces que?

ya si?

esta es la buena?

todos con la careta de toros???

El Bastardo

https://www.thestreet.com/story/13942459/1/what-biotech-investors-can-expect-from-the-j-p-morgan-healthcare-conference-2017.html

Veremos cómo se presentan hoy nuestras Farmas ....de momento a mí me toca esperar , visto el movimiento alcista de todas las que tengo en el punto de mira . Mi reflexión , es que el tiro puede que esté acertado , pero me mantendré fiel a mi sistema y esperare a que se den los valores previstos .
Mi sistema es claro , puede que suba 2/3 días , para caer 6/7 días ...así que los especialistas en cortos , disfrutaréis de un año más con ventaja respecto a los que apostamos por la subida ...aunque sea de céntimos ...jjjj😉...ojo , es solo una opinión y unos datos extraídos de un sistema muy personal .

SYN

Dentro largo 0,95

Synthetic Biologics' C. difficile mid-stage study meets main goal

http://in.reuters.com/article/us-synthetic-study-idINKBN14P1C2?feedType=RSS&feedName=health&utm_source=Twitter&utm_medium=Social&utm_campaign=Feed%3A+reuters%2FINhealth+%28News+%2F+IN+%2F+Health%29

Title: Novavax to Present at the 35th Annual J.P. Morgan Healthcare Conference

Date(s): 5-Jan-2017 8:05 AM

For a complete listing of our news releases, please click here

GAITHERSBURG, Md., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that management will present at the 35th Annual J.P. Morgan Healthcare Conference.

Presentation details are as follows:

Date: Thursday, January 12, 2017
Time: 9:30 am U.S. Pacific Time
Location: California East room, Westin St. Francis Hotel, San Francisco
Live webcast: novavax.com, "Investors"/ "Events"

RIGL

Llevo varios dias tradeandola... estoy dentro a 2.56.

Acaba de presentar datos de una Phase II.

http://www.prnewswire.com/news-releases/rigel-provides-business-updates-and-preliminary-data-in-iga-nephropathy-300386082.html

Un saludo

HALO

Bastardo: followers, did you read the PR closely? Seems like they’re only reporting positive results from a subset of pancreatic cancer pats.

Phase 2 Study in Pancreas Cancer Meets Primary Endpoint

http://www.streetinsider.com/Corporate+News/Halozyme+Therapeutics+%28HALO%29+Phase+2+Study+in+Pancreas+Cancer+Meets+Primary+Endpoint/12395710.html?si_client=intbro

CTIC

Dentro corto a 4,88. Hizo reverse 1/10 anteayer y le toca montar un nuevo ensayo.

CTI BioPharma Announces Removal Of Full Clinical Hold On Pacritinib

The new trial, PAC203 plans to enroll up to approximately 105 patients with primary myelofibrosis who have failed prior ruxolitinib therapy to evaluate the safety and the dose response relationship for efficacy (spleen volume reduction at 24 weeks) of three dose regimens: 100 mg once-daily, 100 mg twice-daily (BID) and 200 mg BID. The 200 mg BID dose regimen was used in PERSIST-2. The Company expects to start the trial in the second quarter of 2017.

https://finance.yahoo.com/news/cti-biopharma-announces-removal-full-063000655.html